The Advanced Instrument (AI) and CGT Catapult collaboration focused on three projects that were focused on understanding the impact of osmolality on AAV1 upstream manufacturing.
Project one focused on determining the impact of osmolality on transfection efficiency, using an array of markers including, Cell viability, transfection efficiency, daily metabolites (glutamine, glucose, lactate, and ammonia), and osmolality using the AI OsmoTECH® PRO technology. Viral genome (Vg) and Capsid titers were assessed at 72 hours post-transfection.
Project two assessed the use of osmolality as a decision tool to trigger a feeding regime during AAV1 manufacturing, while project three focused on the scale-up and use of osmolality to inform optimal time of harvest. The final project in the collaboration utilized the Cell and Gene Therapy Catapult suspension-based platform and benchmarked against optimal parameters identified in the first two projects at a 250ml scale using the Ambr® 250 system. The same parameters were assessed as previously mentioned, and the data portrayed in the graphs found on this site.
What Is The Cell and Gene Therapy Catapult?
The Cell and Gene Therapy (CGT) Catapult was established in 2012 as an independent center of excellence to advance the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and full-scale commercialization. With its focus on cell and gene therapy technologies, CGT Catapult works with partners in both academia and industry. CGT Catapult offers a full range of capabilities with state-of-the-art technologies to enable companies to take products into clinical trials. The CGT Catapult works with Innovate UK. For more information, go to ct.catapult.org.uk or visit www.gov.uk/innovate-uk.